TNF-alfa-ellenes antitest-terápia Crohn-betegségben

Translated title of the contribution: Anti-TNF-α antibody therapy in Crohn's disease

Research output: Contribution to journalArticle

Abstract

Crohn's disease is a chronic inflammatory disorder which may affect any part of the gastrointestinal tract. Its pathogenesis is only partially understood; various environmental and host (e.g., genetic, epithelial, immune and non-immune) factors are involved, together initiating a chronic uncontrolled inflammation, which is partly due to an imbalance between pro- and anti-inflammatory cytokines, and a defective apoptosis of lamina propria T cells. Among proinflammatory cytokines, tumour necrosis factor-α (TNF-α) seems to play a central role in Crohn's disease. Over the past years, the increasing knowledge on the pathogenesis of Crohn's disease has led to the development of a number of biological agents targeting specific molecules involved in gut inflammation, including TNF-α and its receptors. This paper reviews the rationale for the use of TNF-α inhibitors in the treatment of Crohn's disease.

Original languageHungarian
Pages (from-to)529-536
Number of pages8
JournalLege Artis Medicinae
Volume17
Issue number8-9
Publication statusPublished - Sep 2007

Fingerprint

Crohn Disease
Tumor Necrosis Factor-alpha
Antibodies
Cytokines
Inflammation
Tumor Necrosis Factor Receptors
Biological Factors
Therapeutics
Gastrointestinal Tract
Mucous Membrane
Anti-Inflammatory Agents
Apoptosis
T-Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

TNF-alfa-ellenes antitest-terápia Crohn-betegségben. / Lakatos, P.; Lakatos, L.

In: Lege Artis Medicinae, Vol. 17, No. 8-9, 09.2007, p. 529-536.

Research output: Contribution to journalArticle

@article{b2f1a3c8b86a4e6c9412530d5713f86c,
title = "TNF-alfa-ellenes antitest-ter{\'a}pia Crohn-betegs{\'e}gben",
abstract = "Crohn's disease is a chronic inflammatory disorder which may affect any part of the gastrointestinal tract. Its pathogenesis is only partially understood; various environmental and host (e.g., genetic, epithelial, immune and non-immune) factors are involved, together initiating a chronic uncontrolled inflammation, which is partly due to an imbalance between pro- and anti-inflammatory cytokines, and a defective apoptosis of lamina propria T cells. Among proinflammatory cytokines, tumour necrosis factor-α (TNF-α) seems to play a central role in Crohn's disease. Over the past years, the increasing knowledge on the pathogenesis of Crohn's disease has led to the development of a number of biological agents targeting specific molecules involved in gut inflammation, including TNF-α and its receptors. This paper reviews the rationale for the use of TNF-α inhibitors in the treatment of Crohn's disease.",
keywords = "Adalimumab, Certolizumab, Inflammatory bowel disease, Infliximab, Treatment",
author = "P. Lakatos and L. Lakatos",
year = "2007",
month = "9",
language = "Hungarian",
volume = "17",
pages = "529--536",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "8-9",

}

TY - JOUR

T1 - TNF-alfa-ellenes antitest-terápia Crohn-betegségben

AU - Lakatos, P.

AU - Lakatos, L.

PY - 2007/9

Y1 - 2007/9

N2 - Crohn's disease is a chronic inflammatory disorder which may affect any part of the gastrointestinal tract. Its pathogenesis is only partially understood; various environmental and host (e.g., genetic, epithelial, immune and non-immune) factors are involved, together initiating a chronic uncontrolled inflammation, which is partly due to an imbalance between pro- and anti-inflammatory cytokines, and a defective apoptosis of lamina propria T cells. Among proinflammatory cytokines, tumour necrosis factor-α (TNF-α) seems to play a central role in Crohn's disease. Over the past years, the increasing knowledge on the pathogenesis of Crohn's disease has led to the development of a number of biological agents targeting specific molecules involved in gut inflammation, including TNF-α and its receptors. This paper reviews the rationale for the use of TNF-α inhibitors in the treatment of Crohn's disease.

AB - Crohn's disease is a chronic inflammatory disorder which may affect any part of the gastrointestinal tract. Its pathogenesis is only partially understood; various environmental and host (e.g., genetic, epithelial, immune and non-immune) factors are involved, together initiating a chronic uncontrolled inflammation, which is partly due to an imbalance between pro- and anti-inflammatory cytokines, and a defective apoptosis of lamina propria T cells. Among proinflammatory cytokines, tumour necrosis factor-α (TNF-α) seems to play a central role in Crohn's disease. Over the past years, the increasing knowledge on the pathogenesis of Crohn's disease has led to the development of a number of biological agents targeting specific molecules involved in gut inflammation, including TNF-α and its receptors. This paper reviews the rationale for the use of TNF-α inhibitors in the treatment of Crohn's disease.

KW - Adalimumab

KW - Certolizumab

KW - Inflammatory bowel disease

KW - Infliximab

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=34548631138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548631138&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 529

EP - 536

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 8-9

ER -